Stifel on Alkermes (ALKS): 'big picture we still think orexins have real potential in ADHD'

September 21, 2026 8:16 AM

Stifel analyst Paul Matteis reiterated a Buy rating and $63.00 price target on Alkermes (NASDAQ: ALKS).The analyst comments "We are ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

StreetInsider

Log in to your account:

Stifel on Alkermes (ALKS): 'big picture we still think orexins have real potential in ADHD'

Categories